Synpromics announced as Best Emerging UK Synthetic Biotech Company at OBN Awards 2017
- Posted on 6 October, 2017
London, UK, 6th October 2017 / SynbiCITE congratulates Synpromics as the winner of Best Emerging UK Synthetic Biotech Company at OBN’s 9th Annual Awards Ceremony, held last night at Oxford Town Hall. The OBN Awards celebrate innovation and achievement across the UK life sciences industry, including emerging to late stage R&D companies as well as life science investors.
Synpromics, the leader in gene control, creates highly specific synthetic promoters designed to drive gene expression at the desired level and specificity in any cell type, tissue or environmental condition. The company has developed PromPT®, its multi- dimensional bioinformatics database that enables product-specific promoter design and selection empowering the next generation of cell and gene based medicines and bioprocessing applications.
In sponsoring this award, we are supporting the growth of the UK’s burgeoning synthetic biology industry, a core aim of SynbiCITE.
The 3 finalist companies under consideration for this award were:
• Synpromics Ltd
• Chain Biotech
• Oxford Genetics
Dr John Collins, Commercial Director of SynbiCITE, said “All the SynBio companies at the OBN awards represent the very best of synthetic biology in the UK, and were selected from a broad landscape of more than 110 companies across the country. We are privileged to be able help them work towards commercialisation of ground breaking and disruptive technology, turning up-starts to start-ups, and start-ups to grown-ups.”
You can find out more about the event at http://www.obn-awards.com
For more information, contact:
Dr John Collins, Commercial Director
T: +44 (0) 7876 750 624
Media Relations, Sciad Communications:
Richard Anderson, Managing Partner
T: +44 (0)7973 950376
Notes to Editors
SynbiCITE is a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting the adoption and use of synthetic biology by industry. SynbiCITE is a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting the adoption and use of synthetic biology by industry. SynbiCITE and our partners across the UK and globally are committed to developing this technology through responsible innovation which encompasses ethical, societal and environmental considerations.
Share this article:
People also read
Evonetix makes key appointments to support development of novel gene synthesis technology
CAMBRIDGE, UK, 18 September 2018 – EVONETIX LTD (‘Evonetix’), the company pioneering an innovative approach to scalable and high-fidelity gene synthes...
Buildings made from fungi? Meet London’s pop-up bio-lab innovators
If there’s one place you wouldn’t expect a new biotech research lab to be built, it’s slap bang in the middle of a busy London marketFind out more her...
A Lloyd's Emerging Risk Report
Synthetic biology, the application of engineering principles to genetic modification is a market forecast to grow to $39bn by 2020. In recent years sc...